(MedPage Today) — The FDA has approved droxidopa (Northera) for the treatment of neurogenic orthostatic hypotension, a rare disease that results in a drop in blood pressure when patients try to stand up.
(MedPage Today) — Idiopathic pulmonary fibrosis (IPF) diagnosis in the absence of the tell-tale honeycombing pattern on radiology might not always require surgical lung biopsy, a study showed.
(MedPage Today) — Breast reconstruction after mastectomy increased significantly, but more than a third of eligible patients did not have the procedure during the 10 years ending in 2007, a review of more than 20,000 cases showed.
(MedPage Today) — Paroxysmal atrial fibrillation recurred significantly less often in patients initially treated with radiofrequency ablation (RFA) instead of medication, results of a randomized trial showed.
(MedPage Today) — Nearly three out of five people said a physician’s rating on a website was at least a somewhat important factor when choosing a doctor, survey results published Tuesday found.
(MedPage Today) — A well-known antidepressant reduced agitation in people with probable Alzheimer’s disease, but with some adverse cardiac and cognitive effects, researchers reported.
(MedPage Today) — The chance of a clinically significant infection after ambulatory surgery is relatively small; nonetheless, outpatient surgery related infections account for roughly one in five healthcare-associated infections.
(MedPage Today) — Treatment for primary Sjogren’s syndrome with the B-cell depleting antibody rituximab (Rituxan) failed to provide statistically significant improvements, despite the increasing evidence for B cells in the pathogenesis of this disorder, French researchers reported.
(MedPage Today) — In a push to cover immigrants excluded from the nation’s health reform law, a California state senator has proposed legislation that would offer health insurance for all Californians, including those living here illegally.
(MedPage Today) — New drugs on the horizon hold out the promise of being able to cure up to 90% of people with chronic hepatitis C (HCV). They are also promising to be expensive.